INTRODUCTION
injections, electroporation, gene gun), chemical (liposomes, polymers), and biological (viral vectors) ap-Gene therapy, or the manipulation of human genetic proaches. To date, these techniques have suffered from material to produce a therapeutic effect, is a maturing scilow and variable transfection efficiency, uncontrolled entific field. The underlying principles of gene therapy production of foreign gene products, transient results when have been evolving for over 200 years, beginning in the efficacy has been achieved, and the practical issues of oblate 1700s with the use of cow pox as a vaccine to treat taining and using autologous cells from patients (33) . small pox. Since that time, as our understanding of the Viral delivery is the most common form of gene thergenetic basis of disease states has grown so have the apy under investigation, but it has also been accompaclinical opportunities for the application of gene therapy.
nied by unwanted and potentially very serious side For the foreseeable future, though, gene therapy is foeffects. The ideal viral vector would be easily and inexcused on 1) in situ correction of single-gene defects such pensively produced, would efficiently and stably transas those found in cystic fibrosis, Duchenne muscular duce nonproliferating cells in vivo, and would enable dystrophy, and familial hypercholesterolemia, and 2) the long-term, stable, and safe transgene expression without implantation of genetically modified cells expressing and inducing an inflammatory or immune response. While vecsecreting therapeutic proteins, such as erythropoietin, tor development continues to progress, even the most engrowth hormone, or clotting factors into the systemic couraging systems do not meet these basic criteria. The circulation.
most promising candidates, adeno-associated virus (AAV) While the initial results of gene therapy are encouragvectors and FIV-based lentivirus vectors, can stably and ing, it is apparent that safer gene delivery systems must efficiently transduce nonproliferating cells and can even be developed. The three basic strategies that have emerged be rendered less immunogenic and less inflammatory (33, to introduce a gene into cells include mechanical (direct 41). The current versions of these vectors have disad-2 DUFOUR ET AL.
vantages, however. AAV vectors can only accommodate transcription factor normally found transiently in Sertoli cells, these studies demonstrated that Pem transgenic an-transgenes of less than 4.5 kilobases and are difficult to produce in large quantities (33) . HIV-1-based lentivi-imals could be generated using the Pem Sertoli cell-specific promoter with Pem expression selectively in Sertoli ruses contain residual HIV genes and are also difficult to produce (33) . However, the FIV-based lentivirus will cells throughout all stages of development (45) . Pem, Mullerian inhibiting substance, and other transcription not sero-convert but may recombine with human endogenous retroviruses (33) .
factors (GATA-1, GATA-4, WT-1, Sox9, SF-1, and Spz-1) are expressed in Sertoli cells (4,13,18,39,43, TRANSGENIC ANIMALS AND CELL-BASED 45, 49) . This raises the possibility of operably linking the GENE THERAPY USING SERTOLI CELLS gene sequences of therapeutic proteins to Pem and developing transgenic animals with a very high and selec-Transgenic animals provide an alterative source of transplantable cells capable of providing long-term, sta-tive expression of the desired therapeutic. ble delivery of therapeutic proteins. The underlying princi-THE NATURAL ROLE OF THE SERTOLI CELL ple is straightforward and involves the introduction of IN IMMUNOLOGICAL MODULATION foreign genes into the germ line of an animal using mi-Sertoli cells comprise a major component of the mamcroinjection or retroviral insertion (8, 46) . Because the malian testis and are considered "nurse" cells because foreign genes must be transmitted through the germ line, they provide numerous factors required for the orderly every cell of the animal will contain the genetic matedevelopment and protection (i.e., immunoprivilege) of rial. Transgenic technology has produced transgenic mice, spermatozoa (17). This immune privilege is critical for rats, rabbits, pigs, sheep, and cows (28, 31) . Some of the the protection of developing germ cells because they gene products produced include human growth hormone possess a profile of novel cell surface markers that are and factor VIII (19,23,29). The potential benefits of this recognized as foreign by the immune system (30, 42) . technology are diverse, including increased understand-
The immune system becomes competent during the periing of normal physiology and development, vaccine safenatal phase of development and at that time recognizes ty, production of nutritional supplements and pharmaall present antigens as "self." Germ cells develop after ceuticals, gene therapy, and xenotransplantation. puberty, however, and their new genomic program pro-Here we discuss a new approach for gene therapy usduces autoantigens that are recognized as unique and not ing transgenic Sertoli cells capable of creating a locally part of the family considered "self" by the immune sysimmunoprivileged environment enabling their long-term tem. Without the ability of the immune system to tolersurvival and continued production of a therapeutic proate them, the germ cells would be recognized as foreign tein for delivery to the systemic circulation. More speand subjected to immunologic attack. No clear explanacifically, a recent report presented evidence that GFPtion exists for the immune privilege of the testis, but it expressing transgenic mice could survive and express is believed the Sertoli cells are able to protect the germ the transgene when transplanted into an allogeneic envicells by the creation of the blood-testis barrier (12,34) ronment (9). This report and other transplant data of the and secretion of factors that may lead to local immune use of Sertoli cells have provided a possibility of develtolerance (3,7,22,37,40,47). For instance, Sertoli cells oping an alternative approach to classical gene therapy.
are known to produce FasL (3), transforming growth Cell-based gene therapy is hampered by the lack of an factor-β (TGF-β) (1, 6) , and clusterin (2, 5, 24) , which are abundant, safe, and immunologically acceptable source suspected to have immunoprotective (3,16), anti-inflamof tissue. Sertoli cells overcome these obstacles because matory (27, 44) , and tolerizing properties (2, 20) , respecof their unique ability to secrete a cocktail of cytokines tively. and growth factors capable of locally modulating the immune reaction to transplanted cells (1-3,5,6,17,20,22,24, ECTOPICALLY PLACED SERTOLI CELLS 26, 32, 37, 40, 47) . In principle, transgenic Sertoli cells CREATE A LOCAL IMMUNOLOGICALLY could be engineered and transplanted to produce a de-PRIVILEGED SITE sired therapeutic protein such as clotting factors for hemophilia, EPO for anemia, and dopamine for Parkin-Sertoli cells are being investigated for their ability to create a locally immunoprivileged site in which they as son's disease. Conceivably, expression constructs with a promoter that functions in Sertoli cells could be linked well as cografted cells can survive following transplantation. To date, the greatest efforts have revolved around to a gene sequence for a therapeutic protein and microinjected directly into pronuclei. Interestingly, a recent re-cografting Sertoli cells together with islets or dopaminergic tissues for the treatment of diabetes and Parkin-port by Wilkenson et al. demonstrated that transgenic mice could be created in which the homeobox protein son's disease, respectively. Isolated Sertoli cells 1) engraft and self-protect when transplanted into allogeneic Pem was expressed in Sertoli cells (45) . While Pem is a and xenogeneic environments (3,11,15,21,36,48), 2) pro-planted into the subcutaneous space of SCID mice (unpublished data). After 90 days, the graft was removed tect cografted allogeneic and xenogeneic cells from immune destruction (10, 21, 35, 38, 48) , 3) protect islet grafts, and histologic examination of the transplant site using vimentin immunocytochemistry revealed the presence of allowing for the reversal of diabetes in animal models (10,21,38,48), and 4) enable survival and function of co-viable Sertoli cells with morphological structures resembling the testicular seminferous tubules (Fig. 1C) . In ad-grafted foreign dopaminergic neurons in rodent models of PD (35) . Evidence for the use of transgenic Sertoli cells dition, syngeneic rat Sertoli cells were implanted into the subcutaneous space of rats and after 21 days the ex-as a novel means of enabling cell-based gene therapy is derived from several convergent sources and is de-planted tissue demonstrated a defined formation of tubular structures (Fig. 1D, E) (18) . An interesting observa-scribed below.
tion was the development of a vascular bed associated SERTOLI CELLS SURVIVE WHEN GRAFTED with the Sertoli cells in this relatively avascular space INTO XENOGENEIC HOSTS WITHOUT THE (Fig. 1E) .
The creation and maintenance of a vascular USE OF SYSTEMIC IMMUNOSUPPRESSION
bed is an important component for the development of An essential prerequisite to developing the use of transa successful cell transplant product that will systemically genic Sertoli cells for transplantation is the successful deliver the desired protein. The observation is not surdemonstration that isolated xenogeneic Sertoli cells enprising because Sertoli cells produce several angiogenic graft and protect themselves from immunologic attack when factors including VEGF (25) , PDGF (14), and other protransplanted into a convenient, noninvasive, clinically releteins. These studies have subsequently been supported vant transplant site. Several recent studies indicate that by the demonstration that porcine Sertoli cells are capathis is indeed the case. For instance, neonatal porcine Serble of surviving in a dog. These studies incorporated a toli cells exhibit immunosuppressive properties that allow short course of immunosuppression consisting of deoxthem to survive following xenogeneic transplantation yspergualin (0.5 mg/kg; days 0 to 9), rabbit anti-dog into the renal subcapsular space of rodents (11,15). Cullymphocyte serum (1 cc; days −5 to +5), and cyclotured Sertoli cells were labeled with the fluorescent cell sporin (10-30 mg/kg to maintain plasma levels of 300 tracking probe 5-(and -6) carboxyfluorescein diacetate, ng/ml). Porcine Sertoli cells injected into the subcutanesuccinimidyl ester prior to implantation underneath the ous space of the ear pina were found to survive for 30 kidney capsule of Balb/c mice. Grafts were harvested at days (the only time point examined) as demonstrated by 1, 3, and 6 weeks posttransplantation and assessed for staining for pig MHC (15). The data generated from the presence of Sertoli cells by fluorescence microscopy both small and large animal studies and coupled with (15) and immunohistochemistry for clusterin, a Sertoli the findings that xenogeneic Sertoli cells can survive in cell marker (Fig. 1A) . Sertoli cells survived in all grafts the brain of rats (35, 36) suggest Sertoli cells can survive examined, including those harvested at 6 weeks postas discordant xenografts without the need for extensive transplantation (Fig. 1A) . Additionally, these grafts were immunosuppression. examined by electron microscopy and demonstrated nu-INITIAL STUDIES OF THE ENGRAFTMENT merous ultrastructurally intact Sertoli cells. In a separate OF TRANSGENIC SERTOLI CELLS study, neonatal porcine Sertoli cells were transplanted beneath the kidney capsule of nonimmunosuppressed Prior to generating colonies of transgenic animals Lewis rats (11). Grafts were removed after 4, 20, 30, 40, producing potentially therapeutic proteins, it is impor-60, and 90 days posttransplantation and cell survival was tant to demonstrate that the inclusion of a transgene does confirmed by PCR and immunohistochemistry. Sertoli not modify the inherent immunoprotective abilities of Sercells were detected for at least 90 days by both PCR for toli cells. The commercially available transgenic mice exporcine cytochrome oxidase II, a marker for porcine tispressing a green fluorescent protein [TgN(GFPU)5Nagy] sue, and vimentin immunohistochemistry, a marker for provides an excellent test of this possibility. Initial in Sertoli cells. Histologically, the Sertoli cells were either vitro studies confirmed that the Sertoli cells of these arranged in aggregates or tubule-like structures (Fig. 1B) .
mice express GFP (Fig. 1F) (9) . Subsequently, GFP-positive Sertoli cells were isolated and transplanted under SURVIVAL OF SERTOLI the kidney capsule of SCID mice to ensure that the ex-CELLS TRANSPLANTED IN THE pression of the transgenic protein did not impair the na-SUBCUTANEOUS SPACE tive ability of the transplanted cells to engraft. Thirty and 60 days following grafting, the transplant sites were To confirm that Sertoli cells survive in a site other than the kidney subcapsular space or the brain, neonatal harvested and fluorescent histological analysis confirmed the presence of well-delineated GFP-expressing Sertoli porcine Sertoli cells were isolated, cultured for 2 days, and a total of 3 × 10 6 Sertoli cells were surgically im-cells ( Fig. 1G) (9) . Based on the demonstration that GFP 
